Fox Chase has a wealth of experience treating all types of neuroendocrine tumors. It offers combination therapies and innovative surgical techniques, with a focus on minimally invasive, to offer patients the best chance of a successful outcome. Its doctors are also actively involved in developing new therapies for treating neuroendocrine tumors through clinical trials.
Fox Chase’s multidisciplinary team determines a personalized treatment plan for every patient, which may include systemic therapies, such as targeted therapy, immunotherapy, or chemotherapy, either as standard-of-care or as part of a clinical trial. Systemic therapy may be given before or after surgery and may also be recommended to patients who are diagnosed after cancer has spread to other parts of the body.
Fox Chase’s medical oncologists and radiologists helped develop peptide receptor radionuclide therapy (PRRT), a molecular therapy used to treat NET patients who have advanced-stage NET or who are not candidates for surgery.